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1. RESPIRATORY INFECTIONS 
Marcos I Restrepo and James D Chalmers 
Respirology has made important contributions related to respiratory infections over the past year. In 
this review, we focus on bronchiectasis, pneumonia, tuberculosis and non-tuberculous mycobacteria 
infections as the most relevant topics in the area of respiratory diseases. 
1.1. Bronchiectasis 
Park et al. reported a study of 155 patients with bronchiectasis to identify the predictors of 
radiological progression of the disease.1 Treatment in bronchiectasis aims to reduce inflammation 
and airway infection to prevent further lung damage.2 Therefore identifying the drivers of poor 
outcome is important. In this analysis, older patients, those with lower body mass index (BMI) and 
patients infected with Pseudomonas aeruginosa or non-tuberculous mycobacteria (NTM) were more 
likely to show radiological progression, measured using the Bhalla score.1 In multivariable analysis, 
only P. aeruginosa and BMI were statistically significant. The results are supported by existing 
literature. P. aeruginosa colonisation and BMI are both incorporated into the bronchiectasis severity 
index, a validated prediction tool, and P. aeruginosa in particular is strongly associated with other 
indicators of progression such as quality of life, forced expiratory volume in one second (FEV1), 
exacerbation frequency and mortality.3,4  However, the most important step in the treatment of 
bronchiectasis is identifying the underlying cause, since many causes such as NTM infection, 
rheumatoid arthritis, primary ciliary dyskinesia, immunodeficiency or allergic bronchopulmonary 
aspergillosis require specific treatments.5,6 Gao et al.7 conducted a systematic review into the 
underlying causes of bronchiectasis identified in 56 studies (N=8608).7 The study was limited by the 
high variability in testing across different studies, and the variable definitions used, but was able to 
suggest that 18.3% of bronchiectasis patients have an aetiology with a specific treatment. 7 
1.2. Pneumonia and other respiratory infections 
Among the different respiratory infection papers published in Respirology, the vast majority were in 
the area of pneumonia as evidence of this important health care priority. We now summarize the 
most relevant contributions to the journal, focusing on the mechanism of disease secondary to 
infection, the controversial issue of microbiological diagnosis, biomarkers, treatment, health related 
outcomes and complications of patients with pneumonia. 
Mechanism of disease 
Tang FS et al.8 showed that neutrophils from patients with asthma release CXCL8, NE and MMP-9 in 
response to viral surrogates. In addition, Toll-like receptor (TLR7/8) dysregulation may play a role in 
neutrophilic inflammation in viral-induced exacerbations. This evidence suggest that neutrophils 
carry important immunological properties to directly detect and respond to both viral and bacterial 
pathogens. 8 In addition, out of the three respiratory viruses including rhinovirus, influenza and 
respiratory syncytial virus (RSV), only RSV was able to activate neutrophils. 8 The neutrophil 
activation and inflammation observed in asthma may be the result of the complex interactions 
between infectious pathogens and airway epithelium and smooth muscles. 8 The authors also 
suggest that it may not be only the neutrophil activation that plays the leading role during 
exacerbations, but also the resolution or regulation of neutrophilic inflammation following 
infection.8 In an editorial Vlahos and Bozinovski 9 suggest that neutrophils do indeed play an 
important role in the immune response of patients with asthma. The presence of overactivation of 
neutrophils during exacerbations increases asthma disease severity and emphasises the different 
mechanisms by which neutrophils may contribute to the exacerbation period or the resolution 
period.9 
Microbiological diagnosis 
Appropriate antimicrobial therapy and antimicrobial stewardship requires a knowledge of the 
underlying causative pathogen of community acquired pneumonia (CAP). Several studies published 
in Respirology attempted to address the issue about the aetiology in patients with CAP. Sahuquillo-
Arce et al.used a large Spanish dataset to examine the impact of age on the aetiology of CAP.10 The 
study found that older patients were more likely to have Gram-negative infection, particularly with 
Haemophilus influenzae and enteric Gram-negative organisms. Co-morbidities were as, or more 
important than age, with diabetes being associated with pneumococcal and S. aureus pneumonia, 
and COPD associated with H. influenzae. 10 The study confirms previous reports and points to the 
increasing problem of the aging population changing the microbiology of CAP towards an increase in 
Gram-negative organisms. 10 Along with an aging population, there is also an increasing expansion of 
patients receiving immunosuppressive drugs, such as patients receiving chemotherapy for 
malignancy.11 Guidol et al.12 studied 1723 patients with bacteraemia which included 795 patients 
with neutropenia and underlying malignancy. The most frequent cause was P. aeruginosa and the 
mortality rate was 46.2%. 12.8% of Gram-negative organisms identified were multidrug resistant.12 
This study again emphasises the need to consider unusual or resistant organisms in patients with 
immunosuppression.12 Metersky 13 and colleagues presented data from the large USA Veterans 
Hospital database from 2002 to 2012, and found that a small proportion of patients with risk factors 
for Health Care Associated Pneumonia (HCAP) had pseudomonas pneumonia (1.9%) and MRSA 
pneumonia (1.0%). In order to stratify who had one pathogen or the other, the authors suggest that 
MRSA pneumonia patients were more likely to be males, elderly (age >74 years of age), diabetics, 
have COPD, recent nursing home or hospital stay, recent exposure to fluoroquinolone or antibiotics 
treating Gram-positive organisms, and severe pneumonia. In addition, patients with Pseudomonas 
pneumonia were more likely to have a prior hospitalization, immunosuppression, COPD, hemiplegia, 
recent exposure to inhaled corticosteroids, β-lactam/cephalosporin/carbapenem antibiotics, 
antibiotics against Gram-positive organisms, 'other antibiotics' and severe pneumonia requiring ICU 
admission, vasopressors or use of invasive mechanical ventilation within 48 hours of hospital 
admission.13 These results suggest that the appropriate selection of antibiotics may be driven by 
identifying the characteristics of patients with HCAP due to pseudomonas or MRSA. In an elegant 
editorial Waterer 14 suggest that the key aspect of antibiotic utilization is to know whether the 
pathogen causing pneumonia is present at the time of evaluation, rather than identifying whether 
the patients have HCAP or not. In addition, Dr Waterer14 stresses the point that these pathogen-
specific risk factors had a positive or negative predictive value sufficient to reliably determine 
empiric antibiotic therapy as also recently pointed out in the literature.15 Cillóniz et al.16 presented 
an elegant review manuscript emphasizing the importance and clinical relevance of polymicrobial 
infections as the cause of CAP. The authors suggest that polymicrobial infection is an understudied 
and growing entity with distinct inflammatory, host response and disease related characteristics that 
differ from other patients with CAP.16 
Rapid identification of pathogens is the best solution to this problem. Diagnosis within hours using 
PCR or similar methods is not yet fully established, but matrix-assisted laser desorption/isonization 
time of flight mass spectrometry (MALTI-TOF MS) is now in use in many centres to give a more rapid 
identification of pathogens. Mok et al.17 examined the impact of MALTI-TOF on their practice in 
severe pneumonia, showing that identification of pathogens from bronchoalveolar lavage in severe 
CAP, hospital acquired pneumonia and ventilator associated pneumonia, was more rapid with 
MALDI-TOF resulting in earlier de-escalation of antibiotics.17 
Specific pathogens can usually not be identified from their presenting features alone. Two papers 
reported on the characteristics of less frequently identified pathogens in CAP. An organism 
increasingly identified in hospital acquired pneumonia is Acinetobacter baumannii and its related 
pathogens. It is frequently multidrug resistance and is a challenge globally. Ozbatan et al.18 reported 
on 356 adult patients from Turkey of whom the large majority had ventilator associated pneumonia. 
Mortality was high (53.1% at 30-days) and reduced by combination antibiotic therapy. Adenovirus is 
an unusual pathogen in immunocompetent CAP patients, but Yoon et al.19 reported a large case 
series of 91 patients with adenovirus pneumonia compared to 55 patients without adenovirus 
detected. Not surprisingly, there were no clinical features that could accurately identify an 
adenoviral pneumonia. The authors showed that adenovirus can be associated with the broad 
spectrum of disease, from mild CAP to CAP in the ICU.19 Monocytopenia was the only factor found to 
be clearly different between adenoviral and non-adenoviral CAP.19 Legionnaires disease is a 
relatively common cause of CAP, account for 1-10% of cases outside of epidemics.20,21 While 
Legionella pneumophila is most frequently encountered worldwide, Isenman et al.22 provided a 
timely reminder that Legionella longbeachae is the predominant cause in some regions including 
parts of Australasia. 22 The disease presents similarly to pneumophila, with a middle age to elderly 
male predominance, diarrhoea, myalgia, hyponatraemia and abnormal liver function tests- the 
classical features of Legionnaires disease, all common. Admission to the ICU was common at 25% 
but outcomes were relatively good if appropriate antibiotics were used.22 
Biomarkers and pneumonia 
Procalcitonin (PCT) is thought to be a useful marker when trying to decide whether to withhold 
antibiotics from low risk patients with respiratory infections. Ito et al.tested whether PCT could be 
used to predict mortality. Ito and collaborators23 found C-reactive protein, PCT and CURB65 were 
predictive of 30-day mortality, and PCT was additive to CURB65. In addition to markers of systemic 
inflammation, the journal presented data on markers of coagulation in pneumonia with the latest in 
series from Cangemi et al.24 They showed in 104 patients that multiple markers of thrombosis were 
altered in acute pneumonia with evidence of prothrombotic state. This may contribute to the excess 
risk of cardiovascular disease that is consistently reported in patients with community-acquired 
pneumonia. 25 Another study published by Liu D and collaborators26 presented a systematic review 
and meta-analysis that evaluated the prognostic value of procalcitonin in patients with pneumonia. 
The authors identified 21 studies with 6,007 patients in which high procalcitonin levels was 
associated with an increased risk of death among patients with low severity of illness score 
according to a low CURB-65 score and critically ill patients, respectively.26 In addition, this study 
questions the use of the procalcitonin cut-off of 0.5 ng/ml due to the low sensitivity and the inability 
to recognize patients at risk of death.26 Finally, the study suggested that there are no differences in 
the procalcitonin performance characteristics between patients with CAP and ventilator associated 
pneumonia.26 
Pneumonia treatment 
Beta-lactam plus macrolides have become the standard of care for the management of patients with 
CAP. Horita et al.27 performed a systematic review and meta-analysis evaluating whether beta-
lactam plus macrolide antibiotics lead to better survival than beta-lactam alone in patients with CAP. 
The authors included 14 studies, two open-label randomized controlled trials (RCTs) comprising 1975 
patients, one non-RCT interventional study comprising 1,011 patients and 11 observational studies 
comprising 33,332 patients.27 Horita and collaborators27 found that CAP patients treated with beta-
lactam plus macrolide compared with beta-lactam alone had a lower all-cause death with substantial 
heterogeneity. However, in the subgroup of patients with severe CAP the use of combination 
therapy had a protective effect for mortality compared to beta-lactam antibiotic therapy alone.27 
Therefore, despite the suggested beneficial effect of combination therapy with macrolides observed 
mainly in the severe CAP group, the data are limited by the number of observational studies 
identified in this systematic review.27 
Jefferies et al.28 performed a double-blind randomized controlled trial to assess the clinical efficacy 
of paracetamol as anti-pyretic treatment for adult patients with influenza infection.  The original 
concern was derived from animal models that suggested a higher mortality when infected with 
influenza.28 Among 80 adult patients with influenza-like symptoms and positive influenza rapid 
antigen test, the use of 1g paracetamol four times a day for 5 days was not associated with viral 
shedding, temperature change, time to resolution of influenza illness or improved clinical symptoms 
compared to the placebo treated group.28 A following elegant editorial by MJ Peters29, highlights the 
importance of challenging the collective therapeutic intuition and the conventional general wisdom 
of policy and guidelines regarding therapies such as paracetamol and suggest that similar studies 
should be performed with aspirin or other antiinflammatory medications. 
Pneumonia outcomes and clinical complications 
Quality of care, such as timely antibiotic administration, resuscitation and oxygen therapy, 
determine outcome from CAP.30 Many countries have reduce availability of staff and resources at 
weekends compared to weekdays leading to concerns of a “weekend effect” of increased mortality 
from common diseases. Uematsu et al.31 investigated this in a nationwide Japanese database and 
showed that from 23,532 patients with severe CAP, weekend admission was associated with a 10% 
increase in mortality even after adjustment for confounders. A clue to poorer quality of care was 
suggested by a lower frequency of microbiological tests, but the dataset was not sufficiently detailed 
to dig deeper into other markers of quality of care.31 These data are similar in many countries but 
are controversial because of the different characteristics of patients admitted at weekends and 
therefore the risk of residual confounding. 
Kim et al.32 evaluated the predictors of prolonged stay in patients with community-acquired 
pneumonia and complicated parapneumonic effusions in Korean tertiary cohort of patients. The 
authors performed a retrospective cohort study in 158 CAP patients with complicated 
parapneumonic effusions and identified that patients tended to stay at least 18 days in the hospital 
and require at least 10 days of chest tube placement.32 The most common pathogen was 
Streptococcus viridans and 54% of the patients received intrapleural fibrinolytics.32 A prolonged 
hospital stay was independently associated with fever, lower oxygen level, haemoglobin level, 
neutrophilia, pathogen identification and ineffective pleural drainage, suggesting a possible 
beneficial effect of an early thoracotomy, but further studies are need to test this observation. 32 
 
1.3. Tuberculosis 
During the past year, there were two interesting contributions to the journal in the area of 
tuberculosis. The first corresponds to the work presented from Hong Kong on HIV-infected patients 
by Leung and collaborators. 33 The authors assess the diagnostic characteristics of tuberculin skin test 
(TST), T-Spot-TB (T-Spot) and QuantiFERON-TB Gold-In Tube (QFT) to determine latent tuberculosis 
(LTBI) in this high-risk group of patients. They identified 110 HIV-infected patients without previous 
history of LTBI, with 75% of them receiving anti-retroviral therapy and a median CD4 count (414/μL) 
with low median viral load (<75/μL). 33 The results showed almost complete discordance between 
positive baseline TST (5.5%), T-Spot (5.6%) and QFT (4.9%), respectively. There were no correlations 
between CD4 count or viral load with positive LTBI testing. 33 Test conversion rates were higher for 
QFT (10.7%) and TST (8.9%), and lower in T-spot test (5.0%) with no correlation with CD4 count or 
viral load. More than half of the positive T-spot and QFT results reverted to negative during the 
follow-up period. 33 None of these tests picked up the single case of culture-confirmed tuberculosis 
observed after 798 person-years of follow-up. 33 The authors conclude that the major discordant 
results found in TST, T-spot and QFT tests limit the ability of these tests to identify LTBI patients in 
high-risk populations. 33 In addition, it suggests that programs directed at screening HIV-infected 
patients in intermediate tuberculosis burden areas may lack accuracy and requires further 
assessment.33 
Regarding novel treatments for the management drug resistant tuberculosis, Bai and colleagues34 
tested “Curcumin” as a direct anti-TB and immune response stimulator. Curcumin is a spice of bright 
yellow- colour of turmeric, derived from the root of the perennial herb Curcuma longa. 34 Curcumin 
is recognised as a potent inducer of apoptosis, linked to the mechanism of how-an effector inducer 
used by the macrophages to kill MTB intracellularly MTB. The authors used an in vitro human 
macrophage infection model to test whether curcumin affects MTB survival. 34 The authors found 
that MTB clearance was enhanced by THP-1 human monocytes and primary human alveolar 
macrophages. 34 They also found that curcumin was an inducer of caspase-3-dependent apoptosis 
and autophagy and mediates these anti-MTB cellular functions, in part, via inhibition of nuclear 
factor-kappa B (NFκB) activation. 34 Therefore, curcumin seems to present immunomodulatory 
properties against MTB infection in human macrophages, but further animal and translational 
studies are encouraged in order to treat patients at risk for drug resistance development. 34 
1.4. Non-tuberculous mycobacteria (NTM) 
Several manuscripts addressed the clinical characteristics, the clinical outcomes and the treatment 
of NTM pulmonary infections. The classic patients with NTM is described as being a middle aged 
female with low body mass index (BMI) and Mycobacterium avium infection.  In 2016 the United 
States Bronchiectasis registry has recently published their first results showing 63% of patients with 
bronchiectasis in the US have a history of NTM isolation or disease, the majority of whom were 
female and had M. avium infection. 35 Nishimura et al.36 assessed the prior conceived association 
that body habitus is associated with Mycobacterium avium complex (MAC) pulmonary disease. The 
classic literature regarding MAC, has linked middle-aged white women with thin body habitus with 
the diagnosis of MAC lung disease. The authors found that among 1033 healthy subjects, the body 
habitus was not associated with MAC lung disease.36 Differences may relate to environmental, 
genetic or microbiological differences between Asia and the United States, or differences in the 
included study populations.  
Yeung et al.37 reported a systematic review to determine the health-related quality of life, 
comorbidities and mortality in pulmonary NTM infections. The authors identified 17 studies, mainly 
from Taiwan (n = 5) and the USA (n = 4). 37 This systematic review concludes that there is high clinical 
heterogeneity and important bias limiting the ability to define trends, despite the suggested 
increased health burden from respiratory diseases and increased mortality associated with 
pulmonary NTM disease. 37 In the February issue of Respirology, Ellender et al.38 reported a 
retrospective study of 45 patients treated with intravenous amikacin for difficult NTM. Patients have 
a mixture of M. avium complex, M. abscessus and one case of M. fortuitum and received intravenous 
amikacin as an add-on to multidrug regimens. 38 Reflecting the difficulties in treatment in this patient 
population, sputum conversion was achieved in only 38% but the treatment was well tolerated. 
1.5. Conclusions 
We hope that these important contributions in the area of respiratory infections will assist scientists 
and health care providers in their day to day practice taking care of patients with these problems. 
We as associated editors would like to promote and motivate the scientific community all over the 
world to submit your research findings to the Respiratory journal in order to help disseminate 
research discoveries and advances that might help the patients with respiratory infections. 
 
2. ARDS – FROM PATHOPHYSIOLOGY TO PROGNOSIS 
Yuanlin Song 
2.1. Pathophysiology  
Ventilator-induced lung injury (VILI) is a major drawback of mechanical ventilation when used 
improperly in patients with acute respiratory distress syndrome (ARDS). The exact mechanisms 
leading to VILI have not been completely elucidated but volume trauma, barotraumas, and 
biotrauma have been proposed as likely causes39. Extensive studies using a low tidal volume strategy 
showed improved survival benefit in ARDS patients40, and recent recalculation of lung mechanics 
using large clinical trial data suggested low driving pressure is the main contributor to the survival 
benefit41. Given the fact that, in the majority of cases, driving pressure by itself could not be directly 
correlated to VILI if breathing rate was not included, it has been proposed that lung strain, and 
energy load may collectively account for VILI rather than various single components42.  
Identification ofnovel key factors of particular signalling pathways may provide potential therapeutic 
targets against ARDS. In an animal model, high volume ventilation or cell culture model cyclic stretch 
induced degradation of p120-catenin, an adhesion molecule that plays an important role in 
epithelium integrity. In dissecting the mechanism, inhibition of PKCα could successfully block c-Src 
kinase activation and p120-catenin degradation in VILI model, suggesting inhibition of PKCα may 
have potential application in reducing VILI43.  
2.2. Treatment  
    ARDS has been considered a heterogeneous disease with hyper-inflammation in the lungs and 
systemic circulation. Oxidation has been considered a strong risk factor for ARDS development due 
to endothelium and epithelium damage through reactive oxygen species (ROS) activity. It is 
therefore proposed that N-acteycysteine may attenuate acute lung injury through free radicals 
eradication. However, in a human lung resection study which simulated acute lung injury (ALI), 
perioperative administration of N-acetylcysteine did not prevent local and systemic inflammation 
after lung resection44, in which plasma interleukin-6, 8-isoprostane and ischaemia-modified albumin 
were almost identical between pre- and post-operation. Statin has also been considered an anti-
inflammation medicine and has potential application in ALI/ARDS, however, a meta-analysis 
summarising 13 studies including 12145 patients didn’t show an improvement in clinical outcomes 
following statin administration in high risk ALI/ARDS patients45. According to these two studies, the 
anti-inflammation and anti-oxidation action of these two molecules may not be of benefit in 
ALI/ARDS patients.  
2.3. Prognosis 
Sepsis is the leading risk factor for ALI/ARDS, and it is interesting to know whether the infection site 
(e.g. lung, abdominal cavity, urinary tract, etc) affects the outcome prediction in patients with ALI. In 
a group of sepsis patients (624) who developed ALI (251), there was a strong correlation between 
sepsis location and ARDS development but not in non-ALI sepsis patients. Sepsis due to lung 
infection contributed largely to ALI development compared to other infection sites, and morbidity of 
ALI was associated with higher mortality in sepsis from pulmonary and other sources, but not in 
abdominal sepsis46. This evidence suggests that lung infection and lung infection-induced sepsis is a 
leading cause of ALI with high mortality and morbidity, and deserves a high level of attention in 
research and clinical practice.  
Activin-A belongs to the TGF-beta family of molecules, with a potential role in cell proliferation and 
division. In a study enrolling 138 clinically suspected sepsis patients, high serum Activin-A was 
associated with sepsis severity, APACHE-II score and SOFA score47, suggesting Activin-A may be 
potentially useful in sepsis outcome prediction.  
The weaning process is challenging when the patient has delirium. A study enrolling 393 mechanical 
ventilation patients showed that mental status such as delirium significantly delayed the weaning 
process using the spontaneous breathing test (SBT) method48. When confounding factors were 
balanced, delirium was still associated with difficult but not prolonged weaning.  
Aspiration in non-invasive ventilation is a serious complication and needs to be avoided as much as 
possible. A study using a healthy young and a healthy elder population investigated aspiration rate in 
different ventilation modes (BiPAP, CPAP and control) and showed a high probability of aspiration 
after swallow during BiPAP use49 compared to CPAP and control. This suggests swallow with the 
detection of non-inspiratory flow may increase the risk of aspiration through triggering inspiratory 
support in BiPAP mode, which has been widely used in clinical practice.   
In general, various factors were associated with ARDS patients’ prognosis. Improved understanding 
of risk factors in each patient will enable more accurate prognostication and lead to better outcomes 
in ALI/ARDS. 
 
3. LUNG CANCER 
Christopher Mallow and Lonny Yarmus  
3.1. Imaging 
Both ultra-low dose computed tomography (LDCT) and dynamic contrast enhanced magnetic 
resonance imaging (DCE-MRI) were evaluated in the past year. Murray et al.50 evaluated the use of 
LDCT on asbestos-exposed population screening. Of 906 patients who underwent LDCT for annual 
screening, they identified 104 indeterminate nodules in 77 participants over a 12-month period. 
They found no correlation between the number of nodules and cumulative asbestos exposure, the 
pack years of smoking or time since quitting. Parietal pleural plaques were identified in 64% of 
participants, in which 88.3% were calcified. Visceral Pleural Plaques were identified in 11.7% of 
patients, diffuse pleural thickening in 7.9%, and diaphragmatic plaques in 56.4% of patients. A total 
of 162 (17.8%) of subjects were recalled for further investigation due to indeterminate nodules or 
other incidental findings.  
DCE-MRI was evaluated by Karaman et al.51 to evaluate its use in identifying characters of cystic-
cavitary lung lesions that may aid in distinguishing malignant versus benign lesions in comparison to 
CT alone. This was a prospective study of 36 patients with cystic and/or cavitary lung lesions of 
which 11 were found to have malignant lesions. Inner wall irregularity was more sensitive in 
malignant lesions on DCE-MRI (82% vs 64%), but specificity was higher with the CT (96% vs 88%). 
Due to the DCE-MRI’s ability to better distinguish tissue from fluid, biopsy site was changed in two 
patients, and cancelled in 3 patients who had indeterminate lesions on CT. Malignant lesions had a 
greater increase in contrast enhancement in the early phase and had a higher maximal peak 
(p=0.001). Although these findings were promising, the small study size requires that further 
investigation be performed before formal recommendations can be made in regards to its use in 
screening. 
3.2. Diagnosis and Prognosis 
Guisier et al.53 evaluated the adequacy of molecular analysis of peripheral non-small cell lung cancer 
(NSCLC) sampled by radial-EBUS. They performed 362 radial endobronchial ultrasound (r-EBUS) 
procedures of which 194 cancers were identified, 113 were non-squamous NSCLC and 88 had 
sufficient material for molecular analysis. The mean nodule diameter was 28mm, and all 88 samples 
were analyzed for EGFR, KRAS, ALK, HER2, PI3K and BRAF.  Upper and middle lobe biopsies, as well 
as at least three biopsies were predictive factors of molecular analysis feasibility. The authors 
concluded that multi-gene molecular analysis can be performed in 79% of non-squamous NSCLC, and 
that the sensitivity of molecular analysis, although limited due to repeat sampling in only 22 
patients, is approximately 95%.  
 Prognostic indicators were assessed both using circulating tumor cell counts (CTC) and the 
presence of COPD and emphysema.54,55 Zhang et al.54 investigated whether patients with NSCLC had 
detectable CTC’s that could provide prognostic information. 46 patients were enrolled and CTC’s 
were measured at baseline in all patients. They found a presence of CTC’s in 40 patients, with a 
range of CTC’s from zero to 80 cells/3.2 mL (mean 6.11 cells/3.2 mL). They found that the baseline 
CTC count greater than 8 (unfavorable group) was a predictor of a shorter PFS and OS. The median 
OS in the favorable group (CTC<8) was significantly longer than in the unfavorable group (21.3 vs 9.0 
months; p=0.026). The median PFS was also longer in the favorable group (7.4 vs 5.3 months; 
p=0.018). These remained significant in multivariate analysis.  They did not find a correlation 
between CTC count and tumor size after cycles of chemotherapy.  
 A meta-analysis of studies that evaluated COPD and/or emphysema and survival in patients 
with lung cancer was done by Gao et al.55  They found that the presence of COPD was associated 
with poorer OS in patients with COPD versus without COPD (HR 1.17, p<0.001), although there was 
high heterogeneity amongst the studies (I2=74%, p<0.001). Six of the studies also evaluated DFS and 
found that COPD was also associated with worse DFS (HR 1.52, p=0.03), also with high heterogeneity 
(I2=78%, p<0.001). The presence of emphysema was associated with poorer OS (HR 1.66, p<0.001)). 
The overall conclusion was that there is a strong association between both COPD and emphysema 
and survival.  
3.3. Treatment Modalities 
Numan et al.56 prospectively analyzed a cohort of patients with pulmonary metastases to decipher 
which surgical option, VATS versus thoracotomy, led to superior quality of life (QOL). 100 patients 
were assigned either VATS or thoracotomy, with their SF-36 and Brief Pain Inventory scores assessed 
preoperatively and at 1,3 and 6 months postoperatively. There was a significant difference in bodily 
pain and physical performance at 1 month, favoring the VATS group. VATS patients also had an 
average shorter hospital stay (5 vs 7 days, p<0.001), an average shorter duration of chest drainage (3 
vs 4 days, p=0.005) as well as a mean shorter duration of epidural analgesia (4 vs 5 days, p=0.002). 
Despite this, the two groups performed similarly beyond the 1-month time point, and both returned 
to their baseline QOL scores by 6 months. Due to these initial findings, the authors concluded that 
VATS is the preferable surgical approach in this patient population.  
Systemic immunomodulatory therapy was reviewed by Steven et al57 describing the multiple steps 
that can be manipulated by immune therapy. The first immunotherapy they describe is ipilimumab, 
a monoclonal antibody that binds to CTLA-4 and a phase II study in which phased ipilimumab had 
improved immune-related progression-free survival in comparison to the control group (HR=0.72; 
median 5.7 vs 4.6 months, p=0.05), as well as progression free survival(PFS) (HR=0.69; median 5.1 vs 
4.2 months, p=0.02). Overall survival (OS) also appeared to be higher than the control group (12.2 vs 
8.3 months) although not statistically significant. A post hoc analysis identified that patients with 
squamous cell histology had improved PFS and OS (HR=0.40 and 0.48, respectively).   Further studies 
are ongoing in patients with squamous cell histology to compare chemotherapy alone to 
chemotherapy with phased ipilimumab.  
Nivolumab, a monoclonal antibody to PD-1, has been approved by the FDA for the treatment of 
squamous and non-squamous NSCLC with progression on platinum based chemotherapy, or after 
receiving platinum based chemotherapy. Nivolumab lead to a median OS of 14.9 months, 1-year 
survival of 56% and 2-year survival of 45%. Nivolumab was also compared directly against docetaxel 
in advanced NSCLC. The Nivolumab group had a median OS of 9.2 months versus the docetaxel 
groups median OS of 6.0 months. Median PFS was also higher in the nivolumab group.  Interestingly, 
they did not find any prognostic or predictive benefit if patient’s tumourexpressed PD-L1.  
Pembrolizumab, another PD-1 inhibitor, is approved as second-line treatment for NSCLC after 
chemotherapy. A phase I study, showed a response rate of 19.4% in all patients with advanced 
NSCLC. Median PFS was 3.7 months for all patients, 3.0 months for previously treated patients and 6 
months for untreated patients. Median OS was 12.0 months for all patients, 9.3 months for 
previously treated, and 16.2 months for untreated patients. 
Stevens et al.57 also analyzed literature regarding the use of biomarkers to predict responsiveness to 
immunotherapy. In non-squamous NSCLC, positive PD-L1 expression, in patients treated with 
nivolumab, predicted a better clinical response. Unfortunately, the PD-L1 expression was not 
associated with a clinical response in squamous NSCLC. The complexity of PD-L1 expression leads the 
authors to conclude that it requires further investigation prior to its use as predictive biomarker.  
 
4. PLEURAL DISEASE 
Justin Hewlett and Fabien Maldonado 
4.1. Imaging 
Patients with unexplained pleural effusions often require urgent investigations, and while many 
questions relevant to the diagnostic algorithm of pleural effusions have been addressed, whether an 
effusion should be drained before diagnostic imaging occurs remains an important question. This 
question has now been formally addressed. In 110 patients who underwent medical thoracoscopy 
with paired pre- and post-drainage chest X-rays (32 patients also had computed tomography scans), 
post drainage imaging did not appear to provide additional information. As it is unlikely that more 
definitive information will be forthcoming, it seems reasonable not to delay imaging based on this 
study.58 
4.2. Medical thoracoscopy 
Medical thoracoscopy (MT) is now established as the standard of care after non-diagnostic 
thoracentesis. One issue is whether pleurodesis should be performed in the same setting, which is 
generally justified when malignancy is identified, and if the lung is expandable. An interesting survey 
of experienced thoracoscopists clarifies this issue. Participating clinicians were given 20 video clips 
and asked their opinion on whether each clip represented a malignant (including histologic type) or 
benign process, if the lung was trapped or not, and if they would perform pleurodesis. Clinicians 
were correct 60% of the time (83.5% for metastatic disease, 60% for mesothelioma, and 51.4% for 
benign disease). Interestingly, only 12.5% correctly predicted unexpandable lung, and in 16.9% of 
cases pleurodesis would have been performed for benign disease. These results raise concerns for 
the practice of pleurodesis before histologic confirmation and demonstration of expandable lung.59  
The low specificity of physician assessment of gross appearance of pleural disease on MT highlights 
the need for more rapid pathologic assessment. In a series of 62 patients undergoing MT, rapid on 
site evaluation (ROSE) of biopsy specimens with Hemacolor rapid staining was assessed for accuracy 
compared to clinician impression and histopathologic examination of tissue samples. ROSE had a 
sensitivity of 79.17% and a specificity of 95.59% (accuracy of 88.5%). This compared favorably with 
the thoracoscopist’s impression with sensitivity of 100%, but specificity of only 44.7%. ROSE during 
medical thoracoscopy may become an important component of MT when frozen section analysis is 
not available, with the possible caveat that malignant pleural mesothelioma diagnosis may be 
difficult by ROSE.60 
4.3. Tunnelled Indwelling Catheters 
The long-term integrity of indwelling pleural catheters (IPC) is unknown. Histopathologic assessment 
of 41 IPC used for management of MPE was conducted to assess for the possibility of catheter 
breakdown, tumor growth along the catheter, or invasion into the catheter.  The median indwelling 
duration for the pleural catheters was 126 days. Analysis showed cancer cells found within fibrous 
debris in the lumen of 27% of the catheters, but no evidence of direct tumor invasion or growth 
along catheters surfaces was noted.  Reassuringly, all catheters were intact without evidence of 
breakdown both macroscopically or histologically.61 In an accompanying editorial, Akulian and 
Yarmus suggest that the confirmed durability of IPCs could bring about a new era of treatment for 
pleural or systemic malignancy, with IPC used as a conduit for intrapleural drug delivery, drug-eluting 
devices or as a channel to monitor tumor response and drug concentration.62 
 
5. INTERVENTIONAL PULMONOLOGY 
Justin Hewlett and Fabien Maldonado 
5.1. Diagnostic Bronchoscopy  
Massive bleeding is a rare but life threatening complication of flexible bronchoscopy. A large 12-year 
multicenter retrospective study included 520,343 patients, all patients from 33 tertiary hospitals. 
There were 194 cases of massive bleeding (defined as >100ml of blood loss during bronchoscopy). 
Overall incidence was 0.037%.  Mortality per episode was 10.8%.  Risk factors for mortality were age 
≥ 65 years, tracheal bleeding, blood loss >500ml and occurrence of shock.  This confirmed that while 
the mortality for each individual massive bleed is high, the incidence of massive bleeding during 
flexible bronchoscopy remains a very rare event.63 
Peripheral cryobiopsy is becoming a more commonly used bronchoscopic technique. A few small 
studies have shown that cryobiopsy provides larger samples with better diagnostic yield, but with 
higher complication rates of bleeding and pneumothorax. A meta-analysis of 8 studies comparing 
cryobiopsy to standard forceps biopsy involving 916 patients showed that cryobiopsy allowed 
significantly larger specimens with a higher diagnostic rate (risk ratio 1.36, P = 0.0002) for all lesions.  
Bleeding was assessed in 3 of the studies and showed similar rates of bleeding for cryobiopsy and 
forceps biopsy (23.76% and 20.83% respectively).  However, the largest of the studies, including 563 
patients, showed higher bleeding rates in the cryobiopsy group. The relative diagnostic benefit of 
cryobiopsy over forceps biopsy was greater in interstitial lung disease (RR 1.77, P<0.0001). This 
suggests that cryobiopsy is a reasonably safe and effective procedure. More data are needed.64     
Radial endobronchial ultrasonography with guided sheath transbronchial biopsy (EBUS-GS TBB) is 
recommended for the evaluation of peripheral pulmonary lesions. Whether adding conventional 
biopsies to guided sheath biopsies offers benefits is unclear. A retrospective analysis of 88 patients 
undergoing both procedures was conducted to assess the diagnostic utility of conventional TBB after 
EBUS-GS TBB.  EBUS-GS TBB successfully obtained diagnostic sample in 65% of patients.  Of the 
remaining patients, conventional TBB was able to obtain diagnostic tissue in 48%. Multivariate 
analysis showed that conventional TBB was favored if the shortest distance between the radial EBUS 
probe and the outer border of the peripheral lesion was less than 2.5 mm.65    
5.2. Therapeutic Bronchoscopy 
Iatrogenic tracheal injuries are rare, but potentially life threatening complications of intubation with 
reported incidence rate of 0.05-0.37%.  Prior case series suggest that a conservative approach may 
often lead to spontaneous healing. A retrospective review of the management of 35 cases of 
iatrogenic tracheal injuries over 10 years at one institution was conducted.  Four of these cases were 
associated with tracheo-esophageal fistula (TEF) with 3 managed surgically and 1 managed with 
esophageal stenting due to prohibitive surgical risk.  The remaining 31 who did not have TEF were 
managed conservatively with serial bronchoscopy for non-ventilated patients (7 patients) and either 
placement of the endotracheal or tracheostomy tube below the site of injury or placement of a 
silicone “Y” stent for more distal injuries in mechanically ventilated patients.  Success was achieved 
with this conservative approach in 88.57%. This suggests that a conservative approach to tracheal 
injuries is reasonable in the absence of a TEF.66 
5.3. Sedation 
Fractionated propofol administration (FPA) for sedation can lead to unintended consequences of 
oversedation, hypoxia, and hypotension during bronchoscopy. Target controlled infusion (TCI) 
propofol administration uses a computerized infusion device to target an effect site concentration 
based on patient characteristics with more controlled administration and, perhaps, better safety 
profile.  An unblinded randomized non-inferiority trial comparing FPA to TCI propofol for sedation 
was performed in 77 patients.  TCI was noninferior to fractionated propofol with no significant 
differences in lowest SpO2, procedure length, or recovery time. This suggests that TCI propofol is 
non-inferior to FPA, but did not show a better safety profile in this small study.67 
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